Product Description
Asimadoline is an orally active, selective kappa-opioid receptor agonist and has demonstrated efficacy in several preclinical pruritus models.
Mechanisms of Action: OPRK Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Tioga
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Irritable Bowel Syndrome|Diarrhea
Phase 2: Irritable Bowel Syndrome|Ileus|Diarrhea|Pruritus|Dermatitis, Atopic
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ASMP2006 | P2 |
Completed |
Dermatitis, Atopic|Pruritus |
2017-06-01 |
|
| JapicCTI-121866 | P2 |
Completed |
Irritable Bowel Syndrome|Diarrhea |
2014-03-01 |
|
| ASMP3001 | P3 |
Completed |
Diarrhea|Irritable Bowel Syndrome |
2013-06-01 |
|
| JapicCTI-111470 | P1 |
Completed |
Healthy Volunteers |
2011-07-01 |